Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype
Alan L. Ho(Cornell University), Gary K. Schwartz(Cornell University)
Cited by 77
Related Papers
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
|Journal of Clinical Oncology|2009|573
Aurora Kinases: New Targets for Cancer Therapy
|Clinical Cancer Research|2006|274
90-kDa Heat Shock Protein Inhibition Abrogates the Topoisomerase I Poison-Induced G2/M Checkpoint in p53-Null Tumor Cells by Depleting Chk1 and Wee1
|Molecular Pharmacology|2008|44
MLN-8237: A dual inhibitor of aurora A and B in soft tissue sarcomas
|Oncotarget|2016|34